Cargando…

Interleukin-6 Receptor Polymorphism Is Prevalent in HIV-negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor Levels

Multicentric Castleman Disease is largely driven by increased signaling in the pathway for the plasma cell growth factor interleukin-6. We hypothesized that interleukin-6/interleukin-6 receptor/gp130 polymorphisms contribute to increased interleukin-6 and/or other components of the interleukin-6 sig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stone, Katie, Woods, Emily, Szmania, Susann M., Stephens, Owen W., Garg, Tarun K., Barlogie, Bart, Shaughnessy, John D., Hall, Brett, Reddy, Manjula, Hoering, Antje, Hansen, Emily, van Rhee, Frits
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553080/ https://www.ncbi.nlm.nih.gov/pubmed/23372742 http://dx.doi.org/10.1371/journal.pone.0054610

Ejemplares similares

Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
por: Robak, T, et al.
Publicado: (1998)

Soluble Interleukin-6 Receptor Regulates Interleukin-6-Dependent Vascular Remodeling in Long-Distance Runners
por: Villar-Fincheira, Paulina, et al.
Publicado: (2021)

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease
por: van Rhee, Frits, et al.
Publicado: (2022)

Interleukin-6 receptor inhibition with tocilizumab in various renal involvements associated with multicentric Castleman's disease: a report of three cases
por: Komaba, Hirotaka, et al.
Publicado: (2008)

Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer
por: Casneuf, Tineke, et al.
Publicado: (2016)

Generation of Soluble Interleukin-11 and Interleukin-6 Receptors: A Crucial Function for Proteases during Inflammation
por: Lokau, Juliane, et al.
Publicado: (2016)

Soluble Interleukin‐6 Receptor Is Released from Receptor‐bearing Cell Lines in vitro
por: Nakajima, Toshiharu, et al.
Publicado: (1992)

Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome
por: Chen, Luke Y.C., et al.
Publicado: (2021)

Profile of elotuzumab and its potential in the treatment of multiple myeloma
por: Liu, Yi-Chang, et al.
Publicado: (2014)

A Case of Multicentric Castleman's Disease Having Lung Lesion Successfully Treated with Humanized Anti-interleukin-6 Receptor Antibody, Tocilizumab
por: Higuchi, Tomoaki, et al.
Publicado: (2010)

Lung transplantation for idiopathic multicentric Castleman disease: potential efficacy and tolerability of a humanized anti-interleukin-6 receptor monoclonal antibody
por: Tomioka, Yasuaki, et al.
Publicado: (2021)

Role of Interleukin-6 and Its Receptor in Endometriosis
por: Li, Shihui, et al.
Publicado: (2017)

Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer
por: Schuettfort, Victor M., et al.
Publicado: (2021)

Expression of Interleukin-6 and the Interleukin-6 Receptor Predicts the Clinical Outcomes of Patients with Soft Tissue Sarcomas
por: Nakamura, Koichi, et al.
Publicado: (2020)

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease
por: van Rhee, Frits, et al.
Publicado: (2015)

A Case of Keloids Complicated by Castleman’s Disease: Interleukin-6 as a Keloid Risk Factor
por: Quong, Whitney L., et al.
Publicado: (2017)

Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports
por: Ferrero, Simone, et al.
Publicado: (2021)

Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity
por: Rossi, Jean-Francois, et al.
Publicado: (2021)

Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum
por: Ravi, Arjun K, et al.
Publicado: (2014)

Relationship of Soluble Interleukin-6 Receptors With Asthma: A Mendelian Randomization Study
por: Raita, Yoshihiko, et al.
Publicado: (2021)

The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcome
por: Matsunami, Masatoshi, et al.
Publicado: (2018)

Interleukin-6 receptor in the recent-onset rheumatoid arthritis
por: Montes-Cano, Marco Antonio, et al.
Publicado: (2011)

Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor
por: Dayer, Jean-Michel, et al.
Publicado: (2010)

Interleukin-6 receptor pathways in abdominal aortic aneurysm
por: Harrison, Seamus C., et al.
Publicado: (2013)

Expression of Interleukin 6 signaling receptors in carotid atherosclerosis
por: Ziegler, Louise, et al.
Publicado: (2020)

Liver Injury and Elevated Levels of Interleukins, Interleukin-2 Receptor, and Interleukin-6 Predict the Severity in Patients With COVID-19
por: Luo, Kuan, et al.
Publicado: (2021)

Interleukin-6 and interleukin-6 receptor secretion by chronic lymphatic leukaemia and normal B lymphocytes: effect of PMA and PWM
por: Drucker, I., et al.
Publicado: (1997)

Interleukin-6, but not the interleukin-6 receptor plays a role in recovery from dextran sodium sulfate-induced colitis
por: SOMMER, JAN, et al.
Publicado: (2014)

Interleukin-6/interleukin-6 receptor complex promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells
por: Xie, Zhongyu, et al.
Publicado: (2018)

Donor genetic variants in interleukin-6 and interleukin-6 receptor associate with biopsy-proven rejection following kidney transplantation
por: Poppelaars, Felix, et al.
Publicado: (2021)

Clinical effects of soluble interleukin-6 receptor detection on autoimmune rheumatic disease patients
por: Chen, Meng, et al.
Publicado: (2014)

Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses
por: Spencer, Sarah, et al.
Publicado: (2019)

Role of Interleukin-6 in Depressive Disorder
por: Ting, Emily Yi-Chih, et al.
Publicado: (2020)

Correlations between serum interleukin 6, serum soluble interleukin 6 receptor, and disease activity in systemic juvenile idiopathic arthritis patients treated with or without tocilizumab
por: Vilaiyuk, Soamarat, et al.
Publicado: (2019)

Structural Mimicry of Receptor Interaction by Antagonistic Interleukin-6 (IL-6) Antibodies
por: Blanchetot, Christophe, et al.
Publicado: (2016)

Interleukin-6 (IL-6) Receptor Antagonist Protects Against Rheumatoid Arthritis
por: Li, Songsong, et al.
Publicado: (2016)

Recombinant Production of a Mutant Form of Soluble IL-6 Receptor with Inhibitory Effects against Interleukin-6
por: Feghhi-najafabadi, Saba, et al.
Publicado: (2022)

Interleukin-6-producing Intravascular Large B-cell Lymphoma with Lymphadenopathy Mimicking the Histology of Multicentric Castleman Disease
por: Shiroshita, Kohei, et al.
Publicado: (2020)

TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy
por: Williams, Corinne, et al.
Publicado: (2021)

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
por: Smolen, Josef S, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_p97d3ds159k0oom8vrr30na9ob